Nanomedicines for Breast Cancer Theranostics

0538083 - ÚŽFG 2021 RIV NL eng M - Část monografie knihy
Tiwari, A. P. - Rohiwal, Sonali Suresh
Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines.
Nanomedicines for Breast Cancer Theranostics. Amsterdam: Elsevier, 2020 - (Thorat, N.; Bauer, J.), s. 351-369. Micro & Nano Technologies. ISBN 978-0-12-820017-9
Institucionální podpora: RVO:67985904
Klíčová slova: breast cancer * clinical trials * nanomedicine
Obor OECD: Oncology
https://www.sciencedirect.com/science/article/pii/B978012820016200015X

The existing challenges in breast cancer therapy and treatment has made researchers across the globe to come together and address the issues pertaining to existing therapy. Nanomedicine has emerged as an effective area in treatment of breast cancer therapy. However, toxicity issues of nanomaterial should be taken care of before going on further with clinical trials. In this regard, the countries and agencies have also formed some regulatory guidelines to be followed by scientist and researchers working in this field. The chapter focuses on some common nanomaterials employed for breast cancer therapy, their toxicity issues, possible reasons for causing toxicity, current innovative therapies for cancer treatment, and regulatory aspect of breast cancer nanomedicine.
Trvalý link: http://hdl.handle.net/11104/0315901